Acologix has reported Phase II clinical study data of AC-100, its novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells. The data demonstrated that AC-100 stimulated the formation of new dentin (the hard tissue of teeth that protects the tooth pulp and supports the outer enamel) when applied to tooth defects.
The randomized, double-blind, placebo-controlled trial enrolled 35 patients who were candidates for at least two third-molar (wisdom teeth) extractions. Patients served as their own controls, with one molar treated with 200 ug AC-100 (applied on Days 0, 2 and 4 through the dentin tubules) and the other with a placebo. After two months, the teeth were extracted and evaluated for remaining dentin thickness (RDT), new dentin formation, inflammation and necrosis. Administration of AC-100 resulted in a clear trend in the formation of new dentin compared to placebo.
